Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 2
2003 2
2004 2
2005 3
2006 1
2007 1
2018 3
2019 1
2020 3
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Adult pancreatic islets require differential pax6 gene dosage.
Hamasaki A, Yamada Y, Kurose T, Ban N, Nagashima K, Takahashi A, Fujimoto S, Shimono D, Fujiwara M, Toyokuni S, Seino Y, Inagaki N. Hamasaki A, et al. Among authors: shimono d. Biochem Biophys Res Commun. 2007 Feb 2;353(1):40-6. doi: 10.1016/j.bbrc.2006.11.105. Epub 2006 Dec 4. Biochem Biophys Res Commun. 2007. PMID: 17178107
Comparison of Patient-Led and Physician-Led Insulin Titration in Japanese Type 2 Diabetes Mellitus Patients Based on Treatment Distress, Satisfaction, and Self-Efficacy: The COMMIT-Patient Study.
Ishii H, Nakajima H, Kamei N, Uchida D, Suzuki D, Ono Y, Sato Y, Shimono D. Ishii H, et al. Among authors: shimono d. Diabetes Ther. 2021 Feb;12(2):595-611. doi: 10.1007/s13300-020-00995-8. Epub 2021 Jan 18. Diabetes Ther. 2021. PMID: 33460017 Free PMC article.
Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).
Ishii H, Kamei N, Shimono D, Niiya T, Tosaki T, Kitazawa T, Suzuki D, Wakasa Y, Seino H, Oishi M, Ohashi H, Higami K, Akai H; ONWARD-DPP4 study investigators. Ishii H, et al. Among authors: shimono d. Diabetes Ther. 2023 Oct;14(10):1639-1658. doi: 10.1007/s13300-023-01442-0. Epub 2023 Jul 19. Diabetes Ther. 2023. PMID: 37468684 Free PMC article.
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D; Collaborators in the Repaglinide Glucose Oscillation Study in Fukuoka (REGO-F) trial. Terawaki Y, et al. Among authors: shimono d. Diabetol Int. 2020 Feb 14;11(3):274-282. doi: 10.1007/s13340-020-00426-w. eCollection 2020 Jul. Diabetol Int. 2020. PMID: 32802709 Free PMC article.
Chronic exposure to beta-hydroxybutyrate inhibits glucose-induced insulin release from pancreatic islets by decreasing NADH contents.
Takehiro M, Fujimoto S, Shimodahira M, Shimono D, Mukai E, Nabe K, Radu RG, Kominato R, Aramaki Y, Seino Y, Yamada Y. Takehiro M, et al. Among authors: shimono d. Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E372-80. doi: 10.1152/ajpendo.00157.2004. Epub 2004 Oct 12. Am J Physiol Endocrinol Metab. 2005. PMID: 15479955 Free article.
Correction to: Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study.
Imaizumi S, Shiga Y, Ogawa M, Sako H, Nagata Y, Matsunaga A, Shirotani T, Hoshino F, Yahiro E, Uehara Y, Morito N, Tanigawa H, Shimono D, Fukushima M, Sugihara H, Norimatsu K, Kusumoto T, Saku K, Miura SI; ACADEMIE Study Investigators. Imaizumi S, et al. Among authors: shimono d. Heart Vessels. 2020 Apr;35(4):603-604. doi: 10.1007/s00380-019-01374-5. Heart Vessels. 2020. PMID: 30972549
21 results